A Phase 2 interventional study of 1 drop of 0.375% SYL040012 (bamosiran) and 1 drop of 0.750% SYL040012 (bamosiran) in Open Angle Glaucoma and Ocular Hypertension, sponsored by Sylentis, S.A.. Completed at 21 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-06.
Sponsored by Sylentis, S.A. (part of PharmaMar) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Glaucoma, Open-Angle with a site in Spain — 6 open to participants now, 9 under way, none of them phase 3. Glaucoma, Open-Angle · Spain.
Among the 47 studies in Glaucoma, Open-Angle with a site in Spain, this one is the 12th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2014, is one of 2 in phase 2, and was the 25th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →6 of the 47 studies in Glaucoma, Open-Angle with a site in Spain are open now. Recruiting first, the newest first:
Santen SAS · Sites in Spain, Austria, Belgium and 5 more countries
Ages 18–85
Institut Catala de Retina · Sites in Spain
Ages 50–75
Elios Vision, Inc. · Sites in Spain, Belgium, France and 3 more countries
Ages 40+
Nova Eye, Inc. · Sites in Spain, Germany, United Kingdom
Ages 22+
Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA · Sites in Spain
Ages 18–99
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 5 · Phase 4 9
First in 2002; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 184 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 107 across the 35 interventional studies, 198 across the 12 observational. Of the 35 that completed or were terminated, 16 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 47 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sylentis, S.A., one of the names counted as PharmaMar. Under that name alone:
Sylentis, S.A. is the lead sponsor of 12 studies on the registry; none are open to participants now.
PharmaMar has 2 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
4 of the studies in Glaucoma, Open-Angle with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04524416iSTAR MedicalMINIject Global Long-Term Follow-up Study | 2026-12 |
| NCT05786196Nova Eye, Inc.Multicenter Glaucoma Study Investigating Standalone Canaloplasty | 2026-12 |
| NCT07322965Institut Catala de RetinaEvaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma | 2027-04-30 |
| NCT07235592Santen SASPRESERFLO™ MicroShunt XI Observational PMCF Study With no Control Group | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 47 studies in Glaucoma, Open-Angle with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28 treatment days in patients with elevated intraocular pressure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 drop in each eye once daily for 28 consecutive days
Drug: 1 drop of 0.375% SYL040012 (bamosiran)
1 drop in each eye once daily for 28 consecutive days
Drug: 1 drop of 0.750% SYL040012 (bamosiran)
1 drop in each eye once daily for 28 consecutive days
Drug: 1 drop of 1.125% SYL040012 (bamosiran)
1 drop in each eye once daily for 28 consecutive days
Drug: 1 drop of 1.5% SYL040012 (bamosiran)
1 drop in each eye twice daily for 28 consecutive days
Drug: 1 drop of 0.5 % timolol maleate
Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm
Time frame: Baseline and Day 28
Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm
Time frame: Baseline and Day 14
Change From Baseline in the Glaucoma Quality of Life Questionnaire (GQL-15) Scores Within Each Treatment Arm
The GQL-15 is a 15 item, 4-domain tool. GQL-15 scoring ranges from 0 to 75. Higher scores indicate poorer quality of life.
Time frame: Baseline and Day 29
| Milestone | SYL040012 (Bamosiran) 0.375% Eye Drops | SYL040012 (Bamosiran) 0.750 % Eye Drops | SYL040012 (Bamosiran) 1.125% Eye Drops | SYL040012 (Bamosiran) 1.5% Eye Drops | Timolol Maleate 0.5% Ophthalmic Solution |
|---|---|---|---|---|---|
| Started | 37 | 40 | 37 | 33 | 37 |
| Completed | 36 | 38 | 35 | 33 | 36 |
| Not completed | 1 | 2 | 2 | 0 | 1 |
| mmHg | SYL040012 (Bamosiran) 0.375 % Eye Drops | SYL040012 (Bamosiran) 0.75 % Eye Drops | SYL040012 (Bamosiran) 1.125% Eye Drops | SYL040012 (Bamosiran) 1.5% Eye Drops | Timolol Maleate 0.5% Ophthalmic Solution |
|---|---|---|---|---|---|
| Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm | -2.4 ± 2.6 | -3.2 ± 3.9 | -3.1 ± 2.5 | -3.1 ± 3.2 | -6.1 ± 2.2 |
| mmHg | SYL040012 (Bamosiran) 1.5% Eye Drops | SYL040012 (Bamosiran) Eye Drops 1.125% | SYL040012 (Bamosiran) Eye Drops 0.75% | SYL040012 (Bamosiran) 0.375 % Eye Drops | Timolol Maleate 0.5% Ophthalmic Solution |
|---|---|---|---|---|---|
| Change From Baseline in the Mean Diurnal IOP Within Each Treatment Arm | -2.4 ± 2.6 | -2.9 ± 2.4 | -2.5 ± 2.1 | -2.4 ± 3.1 | -5.8 ± 1.9 |
The GQL-15 is a 15 item, 4-domain tool. GQL-15 scoring ranges from 0 to 75. Higher scores indicate poorer quality of life.
| units on a scale | SYL040012 (Bamosiran) 1.5% Eye Drops | SYL040012 (Bamosiran) 1.125% Eye Drops | SYL040012 (Bamosiran) 0.75% Eye Drops | SYL040012 (Bamosiran) Eye Drops 0.375% | Timolol Maleate 0.5% Ophthalmic Solution |
|---|---|---|---|---|---|
| Change From Baseline in the Glaucoma Quality of Life Questionnaire (GQL-15) Scores Within Each Treatment Arm | 20 ± 8.28 | 20.7 ± 7.68 | 19.4 ± 6.34 | 22 ± 9.65 | 18.7 ± 6.21 |
Collected over 28 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SYL040012 (Bamosiran) Eye Drops Dose A | 0/37 (0%) | 0/37 (0%) | 4/37 (10.8%) |
| SYL040012 (Bamosiran) Eye Drops Dose B | 0/40 (0%) | 0/40 (0%) | 9/40 (22.5%) |
| SYL040012 (Bamosiran) Eye Drops Dose C | 0/37 (0%) | 0/37 (0%) | 6/37 (16.2%) |
| SYL040012 (Bamosiran) Eye Drops Dose D | 0/33 (0%) | 0/33 (0%) | 2/33 (6.1%) |
| Timolol Maleate 0.5% Ophthalmic Solution | 0/37 (0%) | 0/37 (0%) | 2/37 (5.4%) |
| Event | SYL040012 (Bamosiran) Eye Drops Dose A | SYL040012 (Bamosiran) Eye Drops Dose B | SYL040012 (Bamosiran) Eye Drops Dose C | SYL040012 (Bamosiran) Eye Drops Dose D | Timolol Maleate 0.5% Ophthalmic Solution |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/37 | 1/40 | 3/37 | 1/33 | 0/37 |
| Conjunctival hyperaemiaEye disorders | 1/37 | 0/40 | 3/37 | 2/33 | 1/37 |
| Ocular discomfortEye disorders | 0/37 | 3/40 | 0/37 | 1/33 | 0/37 |
| Eye pruritusEye disorders | 2/37 | 1/40 | 0/37 | 0/33 | 1/37 |
| Instillation site painInvestigations | 0/37 | 0/40 | 0/37 | 0/33 | 2/37 |
| NasopharyngitisInfections and infestations | 2/37 | 0/40 | 1/37 | 1/33 | 0/37 |
| Lacrimation increasedEye disorders | 0/37 | 2/40 | 0/37 | 0/33 | 0/37 |
| Vision blurredEye disorders | 0/37 | 2/40 | 0/37 | 0/33 | 1/37 |
| ToothacheGastrointestinal disorders | 0/37 | 2/40 | 0/37 | 0/33 | 0/37 |
| Age, Continuous(years) | SYL040012 (Bamosiran) Eye Drops Dose A | SYL040012 (Bamosiran) Eye Drops Dose B | SYL040012 (Bamosiran) Eye Drops Dose C | SYL040012 (Bamosiran) Eye Drops Dose D | Timolol Maleate 0.5% Ophthalmic Solution | Total |
|---|---|---|---|---|---|---|
| Mean | 60.7 ± 10.4 | 59.4 ± 12.9 | 61.5 ± 10.1 | 62.4 ± 11.1 | 60.2 ± 11.5 | 60.8 ± 11.18 |
| Sex: Female, Male(Participants) | SYL040012 (Bamosiran) Eye Drops Dose A | SYL040012 (Bamosiran) Eye Drops Dose B | SYL040012 (Bamosiran) Eye Drops Dose C | SYL040012 (Bamosiran) Eye Drops Dose D | Timolol Maleate 0.5% Ophthalmic Solution | Total |
|---|---|---|---|---|---|---|
| Female | 25 | 24 | 22 | 24 | 24 | 119 |
| Male | 12 | 16 | 15 | 9 | 13 | 65 |
The record gives a start of Oct 2014, a primary completion of Aug 2015 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2020, 5 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bamosiran